Apa yang Membuat Saham Kesehatan Layak Dipertahankan Selama Resesi?

Key Points

Healthcare may be considered a defensive sector, but not all healthcare stocks make for strong defensive plays.

For one, consider it best to focus on healthcare companies with deep economic moats.

Healthcare companies with strong balance sheets fare far better in a recession.

• 10 stocks we like better than Becton ›

In times of economic uncertainty, investors tend to get defensive. Yet while many consider healthcare a defensive sector, don't assume this means all healthcare stocks are worth holding during a downturn.

To steer clear of not just the value traps but possible safety traps as well, consider it best to use the following two criteria to assess the strength of such names: a wide economic moat, as well as the strength of the company's balance sheet.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Wide moats and sticky revenue

Illnesses may not slow down during a recession, but not all types of healthcare are fully recession-resistant. During slowdowns and recessions, discretionary healthcare spending, such as elective surgeries, preventative care, and more cosmetic medical treatments, takes a back seat. Due to factors such as the availability of generic drugs, customers may opt for lower-cost substitutes to branded pharmaceutical products during challenging times.

Hence, when selecting recession-resistant healthcare stocks, focus on names with wide economic moats and sticky revenue. Among medical device stocks, Becton, Dickinson (NYSE: BDX) is a strong example. During both booms and busts, hospitals rely on the company's medical supplies, lab equipment, and diagnostic products.

Johnson & Johnson (NYSE: JNJ) is another strong choice. As Morningstar analyst Karen Anderson noted last year, J&J has one of the widest moats among healthcare names, primarily due to the moats surrounding its medical technology and pharmaceutical segments.

Strong balance sheets

High debt adds greater risk and uncertainty during a downturn. Along with metrics like debt-to-equity and debt-to-EBITDA (earnings before interest, taxes, depreciation, and amortization), factors like earnings consistency and dividend growth track records can also serve as proxies for financial strength.

With the aforementioned healthcare companies, both have debt-to-equity ratios below 1. Becton, Dickinson and J&J are also Dividend Kings, with 54 and 64 years, respectively, of annual dividend growth. Dividend King status for both companies serves as a testament to their steady growth during both prosperous times and more challenging ones.

When reviewing other healthcare stocks, consider filtering them by these criteria to determine which to buy and/or add to your watch list.

Should you buy stock in Becton right now?

Before you buy stock in Becton, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Becton wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $556,335! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,160,572!

Now, it’s worth noting Stock Advisor’s total average return is 975% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of April 14, 2026. *

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.